Immunocore

Immunocore is a commercial-stage biotechnology company that specializes in the development of T cell receptor (TCR) bispecific immunotherapies. Their mission is to revolutionize the treatment of cancer, infectious diseases, and autoimmune diseases by pioneering and delivering transformative immunomodulating medicines. Their proprietary ImmTAX technology platform is designed to activate or suppress the immune system to target specific diseased cells. The company is currently developing a diverse pipeline of therapies across a broad range of indications, including multiple cancers, HIV, and HBV.

Immunocore has made significant progress in its quest to bring innovative treatments to patients, having launched the world's first approved TCR therapy in 2022. They are actively engaged in clinical trials for several other promising candidates, including treatments for melanoma, HIV, and type 1 diabetes. The company boasts a strong team of visionary leaders with extensive experience in R&D, a commitment to diversity, and a dedication to its mission of improving patient outcomes.

Immunocore offers a flexible work environment, allowing employees to manage their schedules and workloads to fit their individual needs. This includes the option to work remotely, allowing for a greater work-life balance and flexibility.

Immunocore offers a comprehensive benefits package that includes 25 days of annual leave, private health insurance, a defined contribution pension scheme, life insurance, critical illness and income protection, an employee assistance program, enhanced parental pay, subsidized gym membership and more. The company offers similar benefits to its US employees, including 20 days of vacation, an employee assistance program, life and disability insurance, parental leave, medical, dental and vision plan, state-mandated benefits, FSA health and dependent care and a 401(k) retirement contribution.

Immunocore is a commercial-stage biotechnology company committed to radically improving patient outcomes for cancer, infectious diseases, and autoimmune diseases. Their mission is to pioneer and deliver transformative immunomodulating medicines by harnessing the power of the immune system through their proprietary ImmTAX technology platform. This platform allows them to activate the immune system to target and destroy diseased cells or to suppress the immune system to reduce autoimmune responses.

Immunocore promotes a culture built on scientific leadership, collaboration, and respect. They value diversity and entrepreneurial thinking, encouraging employees to take initiative and contribute to a shared mission of delivering transformative medicines to patients. Their STRIDE values - science, trust, integrity, diversity, and entrepreneurship - guide their approach to fostering a supportive and inclusive environment where individuals can thrive and make a difference.

Immunocore believes that innovation is driven by diverse thinking, and is committed to creating an inclusive workplace that values all views and opinions. They are actively working to build a supportive environment where individual contributions can be maximized, fostering a culture of collaboration, respect, and integrity.